Novo-backed ReViral acquired by Pfizer

Novo co-led ReViral's USD 55m Series B in July 2018 alongside New Leaf Venture Partners. 

CR-CP Life Sciences led a later USD 44m Series C in August 2020, with Andera Partners and OrbiMed earlier leading a USD 21m Series A.

The USD 525m price tag includes upfront and development milestones.

Novo said that the deal demonstrates commercial interest from big pharma in infectious diseases, which it describes as an area of high unmet need.

ReViral is a clinical-stage biopharma company focused on discovering, developing and commercialising treatments for respiratory syncytial virus (RSV).

The virus infects around 64 million people a year, resulting in 160,000 deaths globally.

ReViral's lead drug, sisunatovir, is an orally administered inhibitor designed to block the fusion of the virus to the host cell. It significantly reduced viral load in a phase 2 human challenge study in healthy adults and is currently in phase 2 clinical development in infants.

Pfizer says it believes annual revenue for these programmes could exceed USD 1.5bn a year.

Advisors 

Pfizer - Clifford Chance (legal)

ReViral - Centerview and BofA Securities (M&A); Goodwin Procter (legal). 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Healthcare
• UK / Ireland
• Exits
• healthcare
• Andera Partners